A dry-powder inhaler (DPI) is a device that delivers medication to the lungs in the form of a dry powder. DPIs are commonly used to treat respiratory diseases such as asthma, bronchitis, emphysema and COPD although DPIs (such as inhalable insulin Afrezza) have also been used in the treatment of diabetes mellitus. DPIs are an alternative to the aerosol-based inhalers commonly called metered-dose inhaler (or MDI).
Chronic obstructive pulmonary disease will continue to be the fast-expanding application of dry powder inhalers.

The global Dry Powder Inhaler market was valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025.
This report focuses on Dry Powder Inhaler volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dry Powder Inhaler market size by analyzing historical data and future prospect.
Regionally, this report categorizes the production, apparent consumption, export and import of Dry Powder Inhaler in North America, Europe, China, Japan, Southeast Asia and India.
For each manufacturer covered, this report analyzes their Dry Powder Inhaler manufacturing sites, capacity, production, ex-factory price, revenue and market share in global market.

The following manufacturers are covered:
Astrazeneca
3M
GlaxoSmithKline
Novartis
Cipla
Teva
Boehringer Ingelheim
Chiesi Farmaceutici
MannKind
Vectura

Segment by Regions
North America
Europe
China
Japan
Southeast Asia
India

Segment by Type
Single Dose Dry Powder Inhaler
Multi Dose Dry Powder Inhaler

Segment by Application
Asthma
Chronic Obstructive Pulmonary Disease
Pulmonary Arterial Hypertension
Others